<DOC>
	<DOCNO>NCT01863745</DOCNO>
	<brief_summary>The purpose study collect assess long-term safety nilotinib patient nilotinib treatment Novartis-sponsored , Oncology CD &amp; MA study benefit treatment judge investigator .</brief_summary>
	<brief_title>Nilotinib Roll-over Protocol Patients Novartis-sponsored Nilotinib Study Benefiting From Nilotinib Treatment</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Patient currently enrol Novartissponsored , Oncology CD &amp; MA study receive nilotinib benefiting treatment nilotinib , determine investigator . Patient permanently discontinue nilotinib treatment parent study due unacceptable toxicity , noncompliance study procedure , withdrawal consent reason . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ggastrointestinal stromal tumor</keyword>
	<keyword>gastrointestinal ,</keyword>
	<keyword>stromal ,</keyword>
	<keyword>tumor ,</keyword>
	<keyword>GIST ,</keyword>
	<keyword>AMN107 ,</keyword>
	<keyword>nilotinib</keyword>
</DOC>